ACRUX LIMITED — Call Transcript 2016

Jan 24, 2016

ACRUX (ACR) - ASX ANNOUNCEMENT

25 JANUARY 2016

HALF-YEAR INVESTOR CONFERENCE CALL

==> picture [482 x 10] intentionally omitted <==

Acrux (ASX: ACR) today confirms that it will host an Investor Conference Call to discuss the results for the half-year ended 31 December 2015.

Investor Conference Call details:

Date: Thursday 25 February 2016 Time: 11am (Australian Eastern Standard Time)

Conference ID: 3638 1248

Dial-in Details:

Toll Free Dial-in Details: 1800 123 296 Australia: +61 2 8038 5221 New Zealand 0800 452 782 Singapore 800 616 2288 United States 1855 293 1544 United Kingdom 0808 234 0757

A Q&A session will be held following the Company presentation. Shareholders and analysts are encouraged to participate by forwarding questions to investor@acrux.com.au in advance of the Conference Call.

Acrux recommends participants dial in at least 5 to 10 prior to commencement of the call. A recording of the call will be made available in the ‘Investor Centre’ section of the Company website at: http://www.acrux.com.au/

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

Sharon Papworth, CFO and Company Secretary: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a drug development company focused on commercialising topical products using its proprietary drug delivery technology. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless Patch[TM] , a fast-drying and invisible topical application technology. Acrux will continue to innovate and bring its developed products to the market in collaboration with licensees.

For further information on Acrux, visit www.acrux.com.au

==> picture [551 x 83] intentionally omitted <==